GlaxoSmithKline to buy San Mateo-based Sierra Oncology for $1.9B

Glaxo is paying a 39% premium for the rare cancer-focused biotech whose stock has already shot up 82% this year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.